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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).SUMMARYMuscular dystrophies are a heterogeneous group of myopathies, characterized by muscle weakness and degeneration, without curative
treatment. Mesoangioblasts (MABs) have been proposed as a potential regenerative therapy. To improve our understanding of the in vivo
behavior ofMABs and the effect of different immunosuppressive therapies, like cyclosporine A or co-stimulation-adhesion blockade ther-
apy, on cell survival noninvasive cell monitoring is required. Therefore, cells were transduced with a lentiviral vector encoding firefly
luciferase (Fluc) and the human sodium iodide transporter (hNIS) to allow cell monitoring via bioluminescence imaging (BLI) and
small-animal positron emission tomography (PET). Non-H2 matched mMABs were injected in the femoral artery of dystrophic mice
and were clearly visible via small-animal PET and BLI. Based on noninvasive imaging data, we were able to show that co-stim was clearly
superior to CsA in reducing cell rejection and this wasmediated via a reduction in cytotoxic Tcells and upregulation of regulatory Tcells.INTRODUCTION
Muscular dystrophies (MDs) are a heterogeneous group of
muscle wasting diseases caused by impairment of the dys-
trophin-glycoprotein complex (DGC). This results inmem-
brane fragility and contraction-mediated muscle injury. At
present, no regenerative therapy for MDs is available and
glucocorticoids are the only clinically accepted, disease-
delaying drugs with serious long-term side effects (Bushby
et al., 2010).
In healthy individuals, damaged muscles are restored by
endogenous stem cells. This natural process of repair
formed the basis of evaluating different stem cells for their
regenerative potential in MDs. Our group has demon-
strated that mesoangioblasts (MABs), which are vessel-
derived stem cells, have therapeutic potential in several
preclinical models of MDs (Sampaolesi et al., 2003,
2006). These positive results have led to a phase 1 clinical
study in Duchenne (D)MD patients with HLA-matched
MABs (EudraCT #2011-000176-33) (Cossu et al., 2015).
Despite progress into clinical trial, limited information
about the biodistribution and long-term survival of
MABs in vivo is currently available.
To date, histology is the gold standard for evaluating
stem cell engraftment in preclinical research. However,
this is an invasive technique, which provides no wholeStem Cell Repbody information, is prone to sampling errors, and ham-
pers clinical translatability. Therefore, there is a need to
noninvasively monitor stem cell location and survival. To
allow long-termnoninvasive cellmonitoring, cells are indi-
rectly labeled via incorporation of imaging reporter genes
in the DNA of the cell and the encoded protein will specif-
ically convert a substrate or bind and/or take up a reporter
probe. This has some major advantages compared to direct
labeling, as it allows long-term cell monitoring and reflects
cell viability. Both factors are of crucial importance to eval-
uate and optimize stem cell therapy.
To visualize graft survival in vivo, mMABs were trans-
duced with a lentiviral vector encoding a bicistronic imag-
ing reporter gene construct encoding firefly luciferase
(Fluc): Genbank: M15077 / PDB: 1LCI and human sodium
iodide symporter (hNIS): Genbank: U66088 for optical
and radionuclide imaging, respectively. The application of
hNIS allows direct translation toward a clinical setting
because it is of human origin and therefore immunologi-
cally neutral. Furthermore, it is a radionuclide reporter
gene, as itsproteinproduct is capableof accumulating radio-
active isotopes of iodine and pertechnetate (99 mTcO4
).
This allows cellmonitoring via clinically establishednonin-
vasive imaging approaches, namely positron emission
tomography (PET) and single-photon emission computed
tomography (SPECT) (Chung, 2002).orts j Vol. 5 j 1183–1195 j December 8, 2015 j ª2015 The Authors 1183
Figure 1. In Vitro Validation of Reporter Gene Expression in Undifferentiated Transduced mMABs
(A) Visualization of BLI signals in vitro.
(B) Quantitative analysis showed a high and stable BLI signal in both Fluc-hNIS+ and Fluc+ mMABs, which was significantly different
compared to WT mMABs (***p < 0.001) (mean ± SD) (n = 5 IEs).
(C) Uptake experiments with 99mTcO4
 were also performed on different time points and only in Fluc-hNIS+ mMABs a clear uptake (23%)
was observed which resulted in significant differences (****p < 0.0001) (mean ± SD) (n = 5 IEs).
(D) Visualization of BLI signals in vitro when seeded in different cell amounts clearly indicated an increase in BLI signals with increasing
cell number in Fluc expressing mMABs.
(E) Quantitative analysis demonstrated a clear positive linear relationship between photon flux and cell amount in Fluc-hNIS+ and Fluc+
mMABs (R2 = 0.98 and R2 = 0.94).
(F) Also a positive linear correlation between 99mTcO4
 uptake and cell amount in Fluc-hNIS+ mMABs was found (R2 = 0.96), while no
99mTcO4
 uptake was present in Fluc+ and WT mMABs.To allow long-term cell survival of allogeneic MABs,
donor rejection by the host should be avoided. To date, cal-
cineurin inhibitors are standardly used in the clinic as
immunosuppressive drugs despite their modest and vari-
able results and numerous side effects (Fischer et al.,
2011; Patel andKobashigawa, 2004). Also, chronic immune
suppressants render the patients prone to opportunistic in-
fections. Therefore, the research field is evaluating short-
term immune suppressants that induce donor tolerance.
Several groups have demonstrated that by temporarily in-
hibiting the co-stimulatory signals, which are required for
T cell activation, donor tolerance could be achieved (Huber
et al., 2013; Murakami and Riella, 2014). In this project, a
combination of two antibodies undergoing clinical evalua-
tion (cytotoxic T-lymphocyte-associated protein 4-Ig,
CTLA4-Ig and anti-lymphocyte function-associated anti-
gen 1, anti-LFA1) will be used for co-stimulation adhesion
blockade (co-stim) (Schiff et al., 2011; Vincenti et al., 2007).
Our goal for this study was to evaluate whether non-H2
matched mMABs injected in alpha-sarcoglycan null
(Sgca/) mice, which is a well-established model of MD,
could be monitored via bioluminescence imaging (BLI)
and small-animal PET (Duclos et al., 1998). Furthermore,1184 Stem Cell Reports j Vol. 5 j 1183–1195 j December 8, 2015 j ª2015 Thwe wanted to use these noninvasive imaging methods to
assess the efficacy of different immune suppressants on
long-term mMAB survival.RESULTS
Fluc and hNIS Expression Was Functional and Had a
Positive Linear Correlation with Cell Amount
GFP+ mMABs were transduced with a lentiviral vector (LV)
containing either a bicistronic imaging reporter gene
construct expressing Fluc and hNIS or a unicistronic imag-
ing reporter gene expressing Fluc alone. Only Fluc express-
ing mMABs were capable of showing a robust BLI signal
(Fluc+ mMABs 1.37 ± 0.43 3 107 total photon flux, p/s,
and Fluc-hNIS+ mMABs 1.48 ± 0.40 3 107 p/s), while
only a background signal could be observed in wild-type
(WT) mMABs (0.06 ± 0.03 3 106 p/s and p < 0.001) (Fig-
ure 1A). mMABs were maintained in culture and on all
time points a BLI signal was produced in both transduced
mMABs (Figure 1B). To evaluate the functionality of
hNIS, cells were incubated with 99mTcO4
 and a clear tracer
uptake of 23.42 ± 2.48% in Fluc-hNIS+ mMABs wase Authors
Figure 2. Maintained Cell Characteristics and Differentiation Capacity in Transduced mMABs
(A) No difference in expression of surface markers was observed between transduced mMABs and WT mMABs. All mMABs were positive for
the typical markers (Sca-1, CD44, and CD140a) and negative for the endothelial marker CD31.
(B) Both transduced and WT mMABs were capable of fusing/differentiating toward myofibers, indicated via the presence of yellow fibers
due to the overlay of GFP and red stained ACTA1. No GFP could be found in the myofiber differentiation of the C2C12s alone. The scale bar
represents 100 mm.observed, while no uptake was shown in Fluc+ (0.14 ±
0.01%) and WT (0.11 ± 0.07%) mMABs on all time points
(p < 0.0001) (Figure 1C).
To estimate cell survival in vivo, we investigated whether
BLI signals and uptake percentages correlated with cell
amounts. Therefore, mMABs were plated out in different
cell amounts and both BLI signals as uptake percentages
were determined. A clear positive linear correlation be-
tween cell amount and photon flux was shown both for
Fluc+ and Fluc-hNIS+ mMABs (R2 = 0.94 and R2 = 0.98) (Fig-
ures 1D and 1E). Also the tracer uptake resulted in a positive
linear correlation for Fluc-hNIS+ mMABs (R2 = 0.96) (Fig-Stem Cell Repure 1F). Again, no tracer uptake could be observed in
Fluc+ and WT mMABs.
Transduced mMABs Maintained Cell Characteristics
and Myogenic Differentiation Capacity
The impact of the transduction process on the expression
of mMAB cell surface markers was assessed via flow cytom-
etry. Both transduced mMABs and WT mMABs were posi-
tive for typical mMAB surface markers including CD140a,
CD44, and Sca-1 (Figure 2A). In contrast, both transduced
andWTmMABswere negative for CD31, which is an endo-
thelial marker (Figure 2A).orts j Vol. 5 j 1183–1195 j December 8, 2015 j ª2015 The Authors 1185
Figure 3. In Vitro Validation of Reporter Gene Expression in Differentiated Transduced mMABs
(A) Visualization of BLI signals in undifferentiated and differentiated mMABs indicated clear BLI signals in transduced mMABs in both
conditions (n = 3 TR).
(B) Quantitative analysis of BLI signals indicated only a BLI signal in transduced mMABs. There was no difference that could be observed
between BLI signals produced in undifferentiated and differentiated transduced mMABs after normalization to cell amount (mean ± SD).
(C) Quantitative analysis of tracer uptake demonstrated tracer uptake in both undifferentiated and differentiated Fluc-hNIS+ mMABs (n = 3
TR). There was no difference that was observed between both conditions in the Fluc-hNIS+ mMABs (mean ± SD).Preservation of differentiation capacity of transduced
mMABs toward myofibers was assessed via a co-culture
experiment with C2C12s (Figure 2B). After 7 days of
differentiation, cells were stained for GFP, skeletal muscle
alpha 1 actin (ACTA1), which is a myogenic marker, and
clear mMABs derived myofibers could be observed in all
conditions.
Functional Reporter Gene ExpressionWas Maintained
after Differentiation
When mMABs undergo differentiation, their gene expres-
sion profile changes and therefore the expression of our re-
porter genes needed to be re-evaluated (Figure 3). Clear BLI
signals were again only observed in the transducedmMABs
when D-Luciferin was administered in both differentiated
(Fluc+ mMABs 0.89 ± 0.12 3 107 p/s and Fluc-hNIS+
mMABs 1.14 ± 0.60 3 107 p/s) and undifferentiated
(Fluc+ mMABs 1.28 ± 0.16 3 107 p/s and Fluc-hNIS+
mMABs 1.30 ± 0.32 3 107 p/s) conditions. Furthermore,
no difference in photon flux was observed between differ-
entiated and undifferentiated mMABs after correction for
cell amount (Figures 3A and 3B). Also the functionality of
hNIS was assessed and even after differentiation 23.06 ±
2.27% of the tracer was taken up (fold increase compared
to Fluc+ and WT mMABs: 127) (Figure 3C).
Noninvasive Monitoring of Transduced mMABs via
Small-Animal PET in Sgca/ Mice
After in vitro validation of our transducedmMABs, 13 106
Fluc-hNIS+ mMABs were bilaterally injected in the femoral
arteries of Sgca/mice. To prevent rejection of the non-H2
matched mMABs, two different immune suppressant regi-
mens were used, namely CsA and co-stim. Also a group1186 Stem Cell Reports j Vol. 5 j 1183–1195 j December 8, 2015 j ª2015 Threceiving no immune suppression was included. CsA was
administered chronically, while co-stim (consisting of
CTLA4-Ig and anti-LFA1) was only administered on
day 0, 2, 4, and 6, in accordance to the protocol of Huber
et al. (2013).
First, we evaluated the functionality of hNIS in vivo via
small-animal PET. On day 1 and 3 post-injection of the
cells, iodide-124 (124I) was injected intravenously. On
both days, there was a clear tracer uptake in the hind
limbs of cell-injected animals, while it was absent in
sham-injected animals (Figures 4A–4C). Therefore, signifi-
cantly higher standardized uptake values (SUVs) were
observed in the hind limbs of cell-injected mice (co-stim
day 1: 0.28 ± 0.14 and day 3: 0.13 ± 0.05; CsA day 1:
0.22 ± 0.07 and day 3: 0.14 ± 0.04; and no immuno
day 1: 0.18 ± 0.02 and day 3: 0.14 ± 0.01) compared to
sham-injected mice (co-stim day 1: 0.06 ± 0.01 and
day 3: 0.05 ± 0.01; CsA day 1: 0.08 ± 0.02 and day 3:
0.05 ± 0.01; no immuno day 1: 0.06 ± 0.01 and day 3:
0.08 ± 0.01; p < 0.05; and p < 0.01) (Figure 4D). No differ-
ences in SUVs were present between the cell-injected ani-
mal groups.
Evaluating the Efficacy of Immune Suppressants
via BLI
To evaluate the functionality of Fluc in vivo, BLI was
performed on different days after injection (Figure 5). Clear
BLI signals were present in all cell-injected mice, while
only background signals were present in sham-injected an-
imals (maximal photon flux: 3.1 ± 0.63 103 p/s/cm2/stera-
dian, sr). Until day 4, no significant differences in BLI
signals could be observed between the different cell-in-
jected groups (co-stim 27.40 ± 3.75 3 106 p/s/cm2/sr; CsAe Authors
Figure 4. Visualization of Intraarterial
Injected Fluc-hNIS+ mMABs via Small-
Animal PET
(A–C) 1 3 106 Fluc-hNIS+ mMABs were in-
jected bilaterally in the femoral arteries of
Sgca/ mice (n = 4 IR) without immune
suppression or with co-stim or CsA as im-
mune suppression. Sham-injected animals
were also included for all groups (n = 3 IR).
At 1 and 3 days after cell injection, 124I
was administered. Clear tracer uptake could
be observed in the hind limbs of cell-
injected animals (indicated via the yellow
arrows) at day 1 (A) and day 3 post-
injection (B), which was absent in sham-
injected animals (indicated via the white
arrows) (C). The regions where NIS was
endogenously expressed (thyroid, T, and
stomach, S) also were clearly visible,
together with the bladder.
(D) Quantitative analysis clearly demon-
strated significantly higher SUVs in the hind
limbs of cell-injected animals compared
to sham-injected animals (**p < 0.01 and
*p < 0.05) without significant differences
between the different cell-injected groups
(mean ± SD).14.14 ± 2.63 3 106 p/s/cm2/sr; and no immuno 3.24 ±
0.9 3 106 p/s/cm2/sr). At day 7, a significantly higher cell
survival was observed in cell-injected animals with im-
mune suppression (co-stim 14.17 ± 2.44 p/s/cm2/sr and
CsA 10.31 ± 3.20 p/s/cm2/sr) compared to cell-injected an-
imals without immune suppression (0.40 ± 0.123 106 p/s/
cm2/sr and p < 0.05). In the animal groups receiving
CsA as immune suppression, a significantly lower cell
survival was observed compared to animals receiving co-
stim at day 10 post-injection (CsA 2.5 ± 0.7 3 104 p/s/
cm2/sr and co-stim 2.93 ± 0.62 3 106 p/s/cm2/sr). This
significant increase in cell survival in Sgca/ under co-
stim immune suppression remained until day 14 post-
injection (p < 0.05). However, stable cell survival was not
achieved in Sgca/ mice under either immunosuppressive
regimen. The latest time point where mMABs could still
be detected in Sgca/ mice with co-stim was day 21 post-
injection.Stem Cell RepMonitoring mMAB Survival in Nude Mice via Small-
Animal PET and BLI
To assess the impact of the immune systemwe studied nude
mice, which have a deficiency in T cell function. Cardio-
toxinwas administered to thehind limbmuscles to generate
anacutemodel ofmuscledamageand regeneration. In these
mice (n = 10), we injected the right hind limb with Fluc-
hNIS+ mMABs, while in the left hind limb Fluc+ mMABs
were injected as a negative control for our small-animal PET.
After intravenous tracer injection, a clear signal could be
observed in the right hind limb on day 1 and day 3 post-in-
jection (day 1: 0.17 ± 0.04 and day 3: 0.11 ± 0.01), while it
was absent in the left hind limb (day 1: 0.07 ± 0.03 and
day 3: 0.07 ± 0.02) (Figures 6A and 6B). This resulted in
significantly higher SUVs in the right hind limbs compared
to the left hind limbs (p < 0.001) (Figure 6B).
We also performed cell monitoring via BLI in these mice
and since both mMABs express Fluc, both cell grafts wereorts j Vol. 5 j 1183–1195 j December 8, 2015 j ª2015 The Authors 1187
Figure 5. Monitoring of Intraarterial Injected Fluc-hNIS+ mMABs via BLI
(A) 13 106 Fluc-hNIS+ mMABs were injected bilaterally in the femoral arteries of Sgca/ mice without immune suppression (n = 5 IR) or
with co-stim or CsA as immune suppression (n = 6 IR). Sham-injected animals were also included for all groups (n = 5 IR). Robust BLI signals
were present in all cell-injected animals the first days after injection, while only background signal was observed in sham-injected animals.
(B) Quantitative analysis demonstrated that starting from day 7, significantly higher BLI signals were present in cell-injected animals
receiving immune suppression compared to cell-injected animals not receiving immune suppression (*p < 0.05). Starting from day 10 until
day 14, significantly higher cell survival was shown in animals receiving co-stim compared to CsA as immune suppressant (**p < 0.01 and
*p < 0.05) (mean ± SD). Cells were lost in animals without immune suppression at 10 days post-injection, at day 14 post-injection in
animals with CsA, and at day 28 for animals receiving co-stim (see also Figure S2).clearly visible (Figure 6C). In these nudemice, we were able
to longitudinally monitor the mMABs for 4 months via
BLI. After an initial cell decrease, stable cell survival was
achieved as indicated by the presence of a stable BLI signal
after 21 days. Also, no difference in cell survival could be
observed between hNIS+ and hNIS mMABs (Figure 6D).
Ex vivo BLI and histological assessment in another cohort
demonstrated the engraftment of the mMABs in the
gastrocnemius muscles (Figure S1).
Evaluation of the Immunological Status of the
Sgca/ Mice
The fact that only in nudemicemMABs survived for longer
than 4 months and not in the Sgca/ mice indicates1188 Stem Cell Reports j Vol. 5 j 1183–1195 j December 8, 2015 j ª2015 Thinvolvement of the adaptive immune system in cell death
or survival. To assess the immunological status of the
Sgca/ mice under different immune suppressive regi-
mens, the Tcells were isolated from the spleen and the frac-
tion of T helper cells (CD3+CD4+ cells), cytotoxic T cells
(CD3+CD8+ cells), and activated/regulatory T cells (Tregs;
CD3+CD4+CD25+ cells) were evaluated (Figure 7). The frac-
tion of T helper cells was similar in all groups (cell-injected
no immuno 49.13 ± 11.27%; CsA 46.81 ± 3.53%; co-stim
51.99 ± 5.36%; sham-injected no immuno 46.53 ±
10.05%; CsA 56.25 ± 6.46%; and co-stim 55.38 ± 2.68%)
(Figure 7A). The cytotoxic T cells were significantly
increased in all cell-injected animals (no immuno 31.73 ±
2.85%; CsA 32.23 ± 4.98%; and co-stim 22.95 ± 4.28%)e Authors
Figure 6. Monitoring of Intraarterial Injected Fluc+ and Fluc-hNIS+ mMABs via BLI and Small Animal PET
(A) 1 3 106 Fluc+ and Fluc-hNIS+ mMABs were injected in the left and right femoral artery, respectively, of nude mice with acute muscle
damage (n = 10 IR). After 124I administration only in the right hind limbs, the Fluc-hNIS+ cells could be detected, while background signal
was present in the left hind limbs (representative image of day 1 post-injection).
(B) Quantitative analysis resulted in significantly increased SUVs in the right hind limbs compared to the left hind limbs both on day 1 and
day 3 (***p < 0.001) (mean ± SD).
(C) Representative BLI images indicate the feasibility to monitor both Fluc+ and Fluc-hNIS+ mMABs longitudinally via BLI.
(D) Quantitative analysis demonstrated a robust BLI signal, which remained stable starting from day 21 (mean ± SD) (see also Figure S1).compared to sham-injected animals (no immuno 23.9 ±
3.61%; CsA 24.5 ± 5.3%; co-stim 15.72 ± 1.26%; and
p < 0.05) (Figure 7B). Sgca/micewith co-stimhad a signif-
icantly lower fraction of cytotoxic T cells compared to
Sgca/mice treated with CsA or without immune suppres-
sion (p < 0.05 and p < 0.01). For the Tregs, there was a
significant increase in the animals under co-stim (cell
2.35 ± 0.78% and sham2.15 ± 0.75%) compared to injected
Sgca/ mice given CsA (cell 0.75 ± 0.29% and sham 1.1 ±
0.21%) or without immune suppression (cell 0.60 ±
0.26% and sham 0.60 ± 0.27%) (Figure 7C).Stem Cell RepmMAB Survival Correlates with Improved Running
Distance of Sgca/ Mice
To evaluate the potential beneficial effects of the cell-
injected animals, Sgca/ mice (n R 5) were placed on a
treadmill with increasing speed (1 m/min every minute).
The results are shown as relative improvement (%),
namely, increased running distance (Dm) normalized to
baseline (Figures S2A and S2B). At day 14 post-injection,
only cell-injected Sgca/ mice receiving co-stim had an
increased running distance of 104 ± 43% normalized
to baseline. No improvement in running distance wasorts j Vol. 5 j 1183–1195 j December 8, 2015 j ª2015 The Authors 1189
Figure 7. Evaluation of T Cell Populations in Sgca/ Mice
(A) No significant differences in T helper cells could be observed between the different groups (nR 5 IR) (mean ± SD).
(B) A significant increase in cytotoxic T cells was present in cell-injected animals compared to sham-injected animals for all groups
(*p < 0.05) (n R 5 IR). Also, a significant decrease in cytotoxic T cells was observed in animals with co-stim as immune suppressant
compared to the other groups (*p < 0.05 and **p < 0.01) (mean ± SD). There was no difference that was observed between animals without
immune suppression and with CsA as immune suppression.
(C) Co-stim as immune suppressant generated a significantly higher population of Tregs compared to the other groups (*p < 0.05;
**p < 0.01; and ***p < 0.001) (mean ± SD) (nR 5 IR). Again, there was no difference that was observed between animals without immune
suppression and with CsA as immune suppressant.observed in the other cell-injected animals (CsA34 ± 16%
and no immuno 6 ± 20%) or sham-injected animals (co-
stim 17 ± 35%; CsA 24 ± 14%; no immuno 42 ± 14%;
and p < 0.01). At day 28 post-injection, none of the groups
showed signs of improvement. On ex vivo BLI, Fluc-hNIS+
mMABs could be retrieved in the gastrocnemius of cell-
injected animals receiving co-stim at day 14 post-injection,
while no mMABs were found in the other groups (Fig-
ure S2C). At day 28, none of the groups could visualize
the cells on ex vivo BLI (Figure S2D). Histological assess-
ment showed the presence of GFP+ fibers expressing
SGCA in the co-stim suppressed group, while the other
groups had no GFP+ fibers at day 14 post-injection (Fig-
ure S2E). Also on histological assessment at day 28 post-
injection, the cells could not be retrieved in all groups
(Figure S2F).DISCUSSION
MABs are vessel-derived stem cells with a high regenerative
potential for MDs. Sampaolesi et al. (2003, 2006) have
demonstrated that MABs are capable of partially restoring
the DGC in preclinical models of MD and reducing the
associated loss in muscle strength in these animals. The
positive results obtained in these studies have led to a phase
1 clinical trial (EudraCT #2011-000176-33) in DMD pa-
tients (Cossu et al. 2015). Despite this initial translation
into the clinic, limited information on MAB survival and
distribution is currently available in vivo. Also, the effect
of different immune suppressants on MAB survival after
systemic administration has not been investigated. There-1190 Stem Cell Reports j Vol. 5 j 1183–1195 j December 8, 2015 j ª2015 Thfore, the research field would benefit from novel tech-
niques to longitudinally and noninvasively monitor cell
survival. We used an indirect labeling approach, which
allows the monitoring of mMABs via BLI and PET in
Sgca/mice and an acutemuscle damage and regeneration
immune-deficient mouse model.
The indirect labeling approach for cell tracking was used
as it has three major advantages compared to the most
commonly used direct labeling approach. First, only viable
cells are capable of expressing the reporter genes. Second,
the detected imaging signals clearly correlate with cell
amount, as demonstrated in our in vitro experiment. Third,
repeated administration of the tracer can be performed to
allow long-term monitoring. These three properties are of
crucial importance to evaluate cell-mediated therapy.
Long-termmonitoring of cell viability is required for regen-
erative purposes and monitoring of cell growth is impor-
tant as a safety measurement for pluripotent-derived cells,
which have the risk of forming teratomas.
FormMAB visualization, we have opted to integrate both
an optical (Fluc) and a human radionuclide (hNIS) imaging
reporter gene in the genomic DNA of the host cells via LVs
(Sakuma et al., 2012). BLI has a very high sensitivity and is
virtually background-free. Therefore, it is capable of detect-
ing very low cell amounts in vivo. However, it is limited to
preclinical research since the signal produced is visible
light. PET has as major advantage the direct translation
toward a clinical setting. The disadvantage is the lower
sensitivity compared to BLI, however, the sensitivity is still
higher than other clinical devices (Massoud and Gambhir,
2003). The most commonly used radionuclide reporter
gene is the herpes simplex virus type 1 thymidine kinase,e Authors
which has a viral origin and therefore may induce immu-
nological reactions (Gambhir et al., 1999). In this study,
we have used hNIS, which has no potential immunological
consequences due to its human origin (Chung, 2002). Due
to the restricted endogenous expression of NIS (thyroid,
stomach, salivary, and mammary glands), hNIS-based cell
monitoring is feasible in the majority of the body. These
advantages have resulted in several preclinical cell moni-
toring studies (Lee et al., 2013, 2015a, 2015b; Templin
et al., 2012; Wolfs et al., 2014).
We demonstrated that hNIS and Fluc were functional
and remained stably expressed in vitro, even after differen-
tiation. Furthermore, a clear correlation between imaging
signals and cell number was observed in vitro, which is a
prerequisite to noninvasively evaluate cell survival in vivo.
Finally, genomic integration of the reporter gene construct
did not induce any alterations to the cell’s characteristics or
differentiation capacity. Therefore, we can conclude that
we have generated a stable stem cell line expressing imag-
ing reporter genes without altering the functionality of
the cells.
Afterward, Fluc-hNIS+ mMABs were bilaterally injected
into the femoral arteries and successfully monitored via
both BLI and small-animal PET. After systemic administra-
tion, we were clearly able to monitor mMABs for several
days via small-animal PET. Long-term cell monitoring
was not feasible because of cell loss over time and the lower
sensitivity of PET compared to BLI (Massoud and Gambhir,
2003). To overcome this limitation,more potent promoters
combined with enhancers need to be used to increase the
expression levels of the reporter gene (Minn et al., 2014).
One other imaging study has been performed for MAB
therapy of MDs. In this study, a direct cell labeling
approach via iron nanoparticles was performed to monitor
the cells via MRI (Odintsov et al., 2011). This cell labeling
approach is limited by contrast agent dilution, no discrim-
ination between viable and nonviable cells, and non-
specific uptake by macrophages (Li et al., 2008). In the
study of Odintsov et al. (2011) iron oxide labeled MABs
were injected in mdx mice and nonspecific uptake of
nanoparticles by the macrophages was observed. Further-
more, they were not able to visualizemMABs after systemic
delivery.
At present, a major limitation for cell transplantation is
cell rejection by the host (Alpdogan, 2013). Contrasting re-
sults have been found for MABs and their reaction with the
immune system. English et al. (2013) demonstrated that
human MABs are capable of suppressing T cell prolifera-
tion. Guttinger et al. (2006) also observed no activation
of T cells after stimulation with mMABs. However, isolated
T cells from mMAB-injected muscles were clearly reactive
against re-exposure to mMABs. Noviello et al. (2014) also
indicated that humanMABs exposed to inflammatory con-Stem Cell Repditions or during differentiation are capable of inducing
T cell expansion and are becoming sensitive to T cell medi-
ated killing.
In this study, we were able to noninvasively monitor
non-H2 matched mMAB survival and to evaluate both
the reaction of mMABs with the immune system and the
efficacy of different immune suppressants. This imaging-
based assessment has already been demonstrated to be
successful by several other groups (Everaert et al., 2012;
Gheysens et al., 2006; Huber et al., 2013). Currently,
chronic immunosuppressive therapy is the gold standard,
but has modest and variable results in patients and lifelong
immunosuppression makes them prone for secondary ma-
lignancies and opportunistic infections (Fischer et al.,
2011). CsA is a widely used clinical immune suppressant
that blocks T cell activation via blocking of cytokine gene
expression, including interleukin (IL)-2 and IL-4 (Kro¨nke
et al., 1984). However, it is associated with numerous side
effects and variable results in suppressing graft rejection
have been observed (Fischer et al., 2011; Gheysens et al.,
2006; Huber et al., 2013; Patel and Kobashigawa, 2004).
Therefore, novel methods with only short-term suppres-
sion of the immune system are currently under investiga-
tion (Alpdogan, 2013).
Huber et al. (2013) demonstrated that a short regimen of
co-stim (consisting of CTLA4-Ig and anti-LFA-1) outcom-
petes CsA in maintaining cell survival after intramuscular
and intracardiac injection of human embryonic stem cell
(hESC)-derived endothelial cells or hESC-derived cardio-
myocytes, respectively. Co-stim functions via the inhibi-
tion of the co-stimulatory signals that are required for
proper T cell activation. CTLA4-Ig has a higher affinity for
CD80 and CD86, which are present on antigen presenting
cells (APCs), and therefore blocks the CD28-CD80 or CD86
pathway, which is important for T cell stimulation (Boise
et al., 1995). Anti-LFA-1 is responsible for the blocking of
the LFA-1-ICAM-1 pathway and inhibits T cell activation
(Nicolls et al., 2000). It has been demonstrated that the
ICAM-1 pathway played a major role in the sensitivity of
MABs toward T cell mediated rejection (Noviello et al.,
2014).
Our BLI data demonstrated a slower decrease in cell
viability in co-stim treated animals compared to Sgca/
mice without immune suppression or treated with CsA.
This improved cell survival under co-stim, and the inability
of CsA to improve cell survival has also been demonstrated
by others (Everaert et al., 2012; Gheysens et al., 2006;
Huber et al., 2013). The relative stable cell survival the first
days after injection followed by a drastic reduction is indic-
ative of the role of the adaptive immune system. This is in
line with previous publications indicating the importance
of T cells in graft rejection (Rosenberg et al., 1987; Strom
et al., 1975). Despite the beneficial effects of co-stim, stableorts j Vol. 5 j 1183–1195 j December 8, 2015 j ª2015 The Authors 1191
cell survival could not be achieved for more than 21 days
post-injection, which is 15 days after stopping co-stim im-
mune suppression.
A similar co-stim approach using adenoviral mediated
muscle gene transfer by Adriouch et al. (2011) also failed
to demonstrate long-term gene expression. Huber et al.
(2013), however, were able to demonstrate stable cell sur-
vival only after local administrations, either intramuscular
or intracardiac injections, in healthy animals. In contrast,
cell survival in an acute myocardial infarction model was
drastically reduced, highlighting the importance of the
micro-environment for cell survival. In our study, a chronic
dystrophicmodel with concomitant chronic inflammation
was used, which reflects a hostile environment for trans-
planted cells. The latter may partly explain the limited
cell survival.
We further studied the effect of the different immune
suppressants on the immune system and analyzed the
T cell populations of the spleen of the Sgca/ mice. In all
cell-injected animals a clear increase in cytotoxic T cells
could be observed compared to sham-injected animals, in
accordance with previous studies (Rosenberg et al., 1987;
Strom et al., 1975). Also, a lower percentage of cytotoxic
T cells was observed in animals suppressed with co-stim
compared to the other groups. Kitchens et al. (2012) also
observed a reduction in graft specific CD8+ T cells after im-
mune suppression with only anti-LFA-1. Furthermore, an
increase in Tregs in mice suppressed with co-stim was
demonstrated. Tregs are well known for their ability to pre-
vent autoimmunity and have been implicated in reducing
allograft rejection after transplantation (Anderton and Li-
blau, 2008; George et al., 2008; Sakaguchi et al., 1995)
Therefore, we can conclude that the immune system
clearly interacts and rejects the non-H2 matched mMABs,
with the cytotoxic T cells as major players for the immuno-
logical clearance. Also, co-stim is a better immune suppres-
sant than CsA, since it is capable of reducing the number of
cytotoxic T cells and increasing the number of Tregs.
The impact of T cell mediated cell killing could also be
demonstrated via the evaluation of the running distance
in mMAB treated animals. At day 14 post-injection,
improvement of running distance was only present in
mMAB-injected animals with co-stim, which were also
the mice with the strongest mMAB survival at that time
point. This indicates the importance of a sufficient number
of surviving transplanted cells to obtain functional
improvement. The other cell-injected groups had a
drastically lower cell amount (20-fold) and hence had no
functional improvement. Since cell survival was not main-
tained formore than 21 days, the improvement observed at
day 14 was lost 28 days post-injection.
The cell injections were repeated in immune-deficient
mice, which were given cardiotoxin intramuscularly to1192 Stem Cell Reports j Vol. 5 j 1183–1195 j December 8, 2015 j ª2015 Thgenerate an acute model of muscle damage and regenera-
tion. Stable and long-term cell survival could be observed
via BLI. This furthermore indicated the potential ofmMABs
as a regenerative cell type for MDs. It also demonstrates the
crucial role of the immune system in cell survival.
The limitations of our study are the inability to detect
very low cell amounts via the imaging techniques (<500
cells for BLI; < 1 3 105 cells for small-animal PET) and the
potential increased immunogenicity of the cells because
of reporter gene expression. However, the sensitivity of
BLI might be sufficient to detect biologically significant
cell survival, and the additive values of noninvasive cell
monitoring still outweigh the invasive golden standard.
And once in a clinical setting, only hNIS will be used and
since this is a human radionuclide reporter gene, no
immune response against the reporter gene product will
occur.
Conclusion
In this study, we noninvasively monitored mMABs via BLI
and small-animal PET in animal models of MD. The pres-
ence of a human radionuclide reporter gene allows cell
detection in a clinical setting and therefore can help opti-
mize stem cell therapies for MD. Our imaging approach
allows assessing the efficacy of different immune suppres-
sants on cell rejection. In this study, we showed that co-
stim was significantly superior to CsA, even though the
effect is only transient. Furthermore, we demonstrated
that mMABs are susceptible to cytotoxic T cell mediated
cell death in an inflammatory environment and that co-
stim exerts its beneficial effects on cell death by reducing
cytotoxic T cells and increasing Tregs.EXPERIMENTAL PROCEDURES
Cell Culture
C2C12s (Sigma-Aldrich) andmMABswere cultured at 37C in a 5%
CO2 humidified incubator under normoxic conditions. C2C12
growth medium (GM) consisted of DMEM, 10% heat-inactivated
fetal bovine serum (FBS), 1% L-glutamine, 1% Penicillin Strepto-
mycin (Pen-Strep) and 1% sodium pyruvate. And mMAB GM
consisted of DMEM supplemented with 20% FBS, 1% Pen-Strep,
1% L-glutamine, 1% sodium pyruvate, 1% nonessential amino
acids, and 0.2% b-mercaptoethanol. All GM components were ob-
tained from Life Technologies.
First, transposon integration of CAGGS-GFP in the mMABs was
achieved with a Sleeping Beauty Transposon (Quattrocelli et al.,
2014).
There were two multicistronic LVs that were obtained from the
Leuven Viral Vector Core (KU Leuven). In the first vector, the
human elongation factor 1 alpha (hEF1a) drives the expression
of the triple FLAG tagged Fluc (3FLAGFluc), Thosea asigna virus
2A (T2A), hNIS, and a puromycin resistance gene (PuroR)
(LV_hEF1a-3FLAGFluc-T2A-hNIS-IRES-PuroR). The second vectore Authors
only contains Fluc and PuroR (LV_hEF1a-3FLAGFluc-IRES-PuroR).
The mMABs were transduced with these LVs by incubating the
cells with the vector (P24: 4.68 3 105 pg/105 cells for LV_hEF1a-3
FLAG Fluc-T2A-hNIS-IRES-PuroR and P24: 3.1 3 105 pg/105 cells
LV_hEF1a-3FLAGFluc-IRES-PuroR) for 2 days and afterward
selected by supplementing the GM with 1.5 mg/ml puromycin
(Merck Millipore).
In Vitro Experiments
In Vitro Tracer Uptake
WT, Fluc+ or Fluc-hNIS+ mMABs were plated in triplicate under
growth and differentiation medium. At the day of analysis, cells
were incubated with 99 mTcO4
 tracer solution (0.74 MBq/ml in
DMEM) for 1 hr. Afterward, cells were rinsed with ice-cold PBS
and supernatant was collected. The cells were lysed and collected.
The radioactivity of the pellet and supernatant was measured by
2480 Wizard2 Automatic Gamma Counter (PerkinElmer). The re-
sults were adjusted for tracer decay. Uptake values were corrected
for cell amounts in the according samples as measured via the
NucleoCounter NC-100 system (ChemoMetec).
In Vitro BLI
WT, Fluc+, or Fluc-hNIS+ mMABs were plated in triplicate under
growth and differentiation medium. At day of analysis, 0.3 mg/l
D-Luciferin (Promega, Benelux) was added to the mMABs and
the emitted light photons were detected with the IVIS Spectrum
(Caliper Life Sciences). The signal was corrected for cell number
and expressed as p/s per 105 cells. In vitro BLI signals were analyzed
with Living Image version 4.2 (Caliper Life Sciences).
Immunohistochemistry
Samples were fixed with 4% paraformaldehyde (PFA) (Kodak) in
PBS for 15 min, rinsed, and subsequently incubated with 0.2%
triton (Triton X-100, Sigma-Aldrich) in 1% BSA in 13 PBS
(Sigma-Aldrich) for 30 min. Samples were again rinsed and after-
ward donkey serum (1/10 diluted in 1% BSA, VWR) was added
for 60 min. Next, samples were incubated with primary antibodies
diluted in 1% BSA, goat anti-GFP (1/500, # ab6673, Abcam) and
rabbit anti-ACTA1 (1/300, #ab50591, Abcam) overnight at 4C.
The following day, samples were rinsed and incubated with the
secondary antibodies anti-goat 488 and anti-rabbit 594 Alexa
Fluorphore (both 1/500 in 1% BSA, #Z25002, #Z25307, Life Tech-
nologies) for 1 hr at room temperature (RT). Samples were rinsed
and counterstained using DAPI (10 mg/ml in 1% BSA, Sigma-
Aldrich). Afterward, samples were analyzed with an Eclipse TI
fluorescence inverted microscope (Nikon) using NIS Elements AR
4.11.01 software (Nikon).
Animals
All experiments were approved by the Ethical Committee of the
KU Leuven. Age-matched Sgca/ mice (C57/Bl6 background,
4 months old) were generated by our group. There were 6-week-
old thymic aplasia nude (NMRI-nu) mice that were obtained
from Janvier Labs and received a 10 mM solution of cardiotoxin
(Naja Mossambica Mossambica, Sigma-Aldrich) in the tibialis ante-
rior, gastrocnemicus, and quadriceps muscle of each hind limb.
During manipulations and imaging procedures, mice were
anaesthetized using 2% or 3% isoflurane (IsoVET, 100 mg/g, Euro-Stem Cell Repvet, Piramal Healthcare) in 100% O2 (2 l/min) for Sgca
/ or nude
mice, respectively. There were one million mMABs that were in-
jected in physiological water supplemented with 1/104 heparin
(Heparine LEO, 5.000 I.E./ml, LEO Pharma A/S) bilaterally into
the femoral arteries. Control animals underwent a shamoperation.
Sgca/ mice either received no immunosuppressive therapy,
intraperitoneal (i.p.) CsA (10 ml/g, Neoral Sandimmum, Novartis)
twice weekly starting 1 week before transplantation, or i.p. co-
stim (consisting of anti-LFA-1 andCTLA-4-Ig) according to the pro-
tocol described by Huber et al. (2013). Anti-LFA-1 antibody and
CTLA-4-Ig were bought from BioXCell.In Vivo Imaging
Small-Animal PET
The mice received an intravenous injection of 3.7–5.55 MBq 124I
(PerkinElmer) on day 1 and 3 and an intramuscular injection of
100 ml LASIX (20 mg/ml, Sanofi) as diuretic. At 3 hours later, a
20 min static scan was acquired with the Focus 220 small-animal
PET system (Siemens Medical Solutions USA). A transmission
scan was acquired using a 57Co source (5 mCi, Eckert and Ziegler).
PET images were reconstructed using a maximum a posteriori
(MAP) image reconstruction algorithm and were then analyzed
with PMOD 3.0 (PMOD technologies). SUV was calculated accord-
ing to the following formula:
SUV =
Activity concentration in organ
Injected activity=weight of animal
:
Volumes of interest were manually positioned around the graft
regions.
BLI
For in vivo BLI scans, mice were placed in the flow chamber of IVIS
Spectrum. Subsequently, 126 mg/kg of D-Luciferin was injected
subcutaneously. Next, consecutive frames were acquired until
the maximum signal intensity was reached. Region of interests
were drawn around the regions injected with Fluc+ or Fluc-hNIS+
mMABs and the maximal radiance (p/s/cm2/sr) was measured
within these regions. Images were analyzed using Living Image
version 4.2.
T Cell Isolation
The spleens of Sgca/ mice were isolated and a single cell suspen-
sion in ice-cold RPMI 1640medium (Life Technologies) was gener-
ated via a 100 mm falcon cell strainer (Corning Life Science DL).
The samples were then centrifuged at 300 g for 10 min at 4C.
Next the pellet was resuspended in ammonium-chloride-potas-
sium (ACK) lysing buffer (Life Technologies) for 5 min at RT and
centrifuged at 300 g for 5 min at 21C. The cells were resuspended
in ice-cold MACS buffer (0.5% BSA and 2 mM ethylenediaminete-
traacetic acid, Sigma-Aldrich, in PBS) and magnetic labeling and
separation of the CD3+ T cells were performed according to the
following protocol: ‘‘CD3ε MicroBead Kit, mouse’’ (MACS Miltnyi
Biotec). T cells were fixed with 2% PFA for 15 min, centrifuged at
1,000 g for 10 min, and stored in PBS.
T Cell Characterization
T cells were stained with APC anti-mouse CD3ε clone 145-2C11
(0.2 mg/ml, #100311), APC/Cy7 anti-mouse CD4 clone GK1.5
(0.2 mg/mL, #100413), PerCP/Cy5.5 anti-mouse CD8a cloneorts j Vol. 5 j 1183–1195 j December 8, 2015 j ª2015 The Authors 1193
53-6.7 (0.2 mg/ml, #100733), and PE anti-mouse CD25 clone
61 (0.2 mg/ml, #102007). All antibodies were obtained from
BioLegend. The solutions were vortexed at 1,000 rpm and incu-
bated for 30 min in the dark at RT. Next, PBS was added, vortexed,
and spun down for 10 min (1,000 g) twice. Afterward, the pellet
was resuspended in PBS and analyzed using the BD FACSCanto
(BD Biosciences).
Statistical Analysis
Data are presented as mean ± SD and are either performed by tech-
nical or independent replicates (TR, IR) or by independent experi-
ments (IE). ANOVA statistical tests were performedwith Tukey post
hoc tests if the samples were normally distributed and had equal
variances. Otherwise, the Kruskal-Wallis statistical tests were per-
formed with Dunn’s test post hoc test. p values < 0.05 were consid-
ered statistically significant. Data were processed using GraphPad
Prism version 5.00 for Windows (GraphPad Software).
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